OmniAb, Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. By leveraging its proprietary technologies and platforms, the company aims to generate a diverse array of high-quality antibodies for various therapeutic applications, focusing primarily on areas such as oncology, autoimmune diseases, and infectious diseases. OmniAb collaborates with other biotechnology and pharmaceutical companies to enhance drug discovery processes, ultimately seeking to advance innovative treatments that can address unmet medical needs. Read More
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates.
OmniAb, Inc. (NASDAQ: OABI) today introduced the launch of the xPloration Partner Access Program, under which current OmniAb partners can purchase the xPloration instrument to significantly enhance their capabilities in antibody discovery and development. xPloration is OmniAb’s proprietary, innovative, high-throughput single B-cell screening platform that leverages machine learning and artificial intelligence.
OmniAb, Inc. (NASDAQ: OABI) today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down following nearly six years of service during a period of key strategic acquisitions and the significant expansion of the scope and size of OmniAb’s partnership base. These Board changes are effective immediately and increase the number of Directors to seven.
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates.
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Tuesday, March 18, 2025 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company’s technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San Diego.
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates.
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Tuesday, November 12, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2024, and provided operating and partner program updates.
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial markets on Thursday, August 8, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies.
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be presenting a corporate overview on Wednesday, June 5th at 8:00 a.m. Eastern time and will be holding one-on-one meetings with investors.
OmniAb, Inc. (Nasdaq: OABI) today announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today the Company presented an overview of xPloration, a high-throughput single B-cell screening platform that leverages machine learning and Artificial Intelligence (AI), in a presentation titled “Deep Screening in Harmony with Artificial Intelligence for Bispecific Antibody Discovery.”
